Published March 29, 2023
Cellevate expands the collaboration with the University of Dundee, UK, to optimize the use of the Cellevat3d™ microcarriers in AAV based production for cell and gene therapy
LUND, Sweden – Cellevate AB, an innovative biotech company that develops the next generation of cell culture systems designed to revolutionize biomanufacturing, has expanded the collaboration with the University of Dundee in the UK to perform cell culture experiments as one of the partners engaged in the validation program of the Cellevat3d™ microcarriers in cell…
Published March 27, 2023
Cellevate supplies nanofiber-based technology for Upstream AAV, lentivirus and cell therapy bioproduction, as part of AdBIOPRO
LUND, Sweden – Cellevate AB, an innovative biotech company that develops the next generation of cell culture systems designed to revolutionize biomanufacturing, announces that AdBIOPRO consortium, the Competence Center for Advanced BioProduction, at Royal Institute of Technology, Stockholm, Sweden, has had its official start on March 22, 2023. This program consists of 24 members of…
Published December 20, 2022
Cellevate awarded Vinnova/STUNS Life Science grant to run Cellevat3d™ microcarriers scale-up validation for AAV production at Testa Center
LUND, Sweden – Cellevate AB, an innovative biotech company that develops the next generation of cell culture systems designed to revolutionize biomanufacturing, today announces that the company has been awarded a grant of 800.000 SEK from Vinnova/STUNS Life Science to run a validation study program for its novel Cellevat3d™ nanofiber based microcarriers at Testa Center…
Published December 1, 2022
Cellevate, Karolinska Institutet and Karolinska University Hospital to collaborate in Vinnova financed project to develop more effective production of stem cell therapies
LUND, Sweden – Cellevate, Karolinska Institutet and Karolinska University Hospital were awarded a grant of 5.25 MSEK in February 2022 from the Swedish Governmental Agency for Innovation Systems (Vinnova) for a collaboration project dedicated to the development of new technologies and techniques for cheaper more effective production of extracellular vesicles (EV) from hematopoietic & mesenchymal stem cells….
Published November 22, 2022
Leading expert in continuous bioprocess for biologics production, Associate Professor, Dr. Véronique Chotteau appointed to Cellevate’s Scientific Advisory Board
LUND, Sweden – Cellevate AB, an innovative biotech company that develops the next generation of cell culture systems designed to revolutionize biomanufacturing, today announces that Associate Professor, Dr. Véronique Chotteau, has been appointed to the company’s Scientific Advisory Board. Dr. Chotteau is the Principal Investigator of the Cell Technology group at KTH (The Royal Institute…
Published November 9, 2022
Cellevate starts using SmiLe’s newly upgraded laboratories equipped for gene therapy applications
LUND, Sweden – Cellevate AB, an innovative biotech company that develops the next generation of cell culture systems designed to revolutionize biomanufacturing, has started performing the cell culture experiments for the validation of the Cellevat3d™ microcarriers in the modern laboratories provided by SmiLe Incubator, located at Medicon Village in Lund. “As SmiLe alumni members, we…
Published June 7, 2022
Cellevate awarded € 2.48 million grant through the European Innovation Council Accelerator competitive program
Cellevate’s proprietary Cellevat3d™ Microcarriers biopharmaceuticals production program to be accelerated towards industrialization LUND, Sweden – Today Cellevate received approval for a two-year € 2.48 million grant funded through the European Innovation Council Accelerator program. The grant is dedicated to develop and scale up for the large-scale commercialization of the nanofiber-based Cellevat3d™ Microcarriers product portfolio, designed…
Published April 21, 2022
Cellevate launches new website today
LUND, Sweden – Cellevate is inviting visitors to explore its newly redesigned website www.cellevate.com. The new website has been created to provide visitors detailed, extensive and up to date information about Cellevat3d™- the single use, scalable and sustainable breakthrough nanotechnology platform and its applications, from R&D to large scale biomanufacturing. On the new website, visitors can also…
Published April 21, 2022
Cellevate appoints Laura Chirica as new CEO- mission to lead the company into large scale commercialization
LUND, Sweden – Laura Chirica has a broad and extensive experience within life science, diagnostics and biotech industry. Her insights include technology development, company and commercialization strategy, organization development, sales and marketing, business development, stock market introduction, project, and program management. Laura has been responsible for large capital projects, portfolios of products and platforms for…